1.1k citations
Counting papers with at most 25 authors, so collaboration author lists do not stand in for the people here.
- Carnegie Mellon UniversityUS3 papers
- Eli Lilly (United States)US3 papers
- Harvard UniversityUS3 papers
- New Jersey Institute of TechnologyUS3 papers
- Pfizer (United States)US3 papers
- United States Military AcademyUS3 papers
- University of WashingtonUS3 papers
- Centre National de la Recherche ScientifiqueFR2 papers
- Duke UniversityUS2 papers
- Janssen Research & Development (United States)US2 papers
- Nektar Therapeutics (United States)US2 papers
- New York UniversityUS2 papers
4 papers · 1 filter
Principal Stratum Strategy: Potential Role in Drug Development
Björn Bornkamp, Kaspar Rufibach, Jianchang Lin +6
A randomized trial allows estimation of the causal effect of an intervention compared to a control in the overall population and in subpopulations defined by baseline characteristi…
Decision Making in Drug Development via Inference on Power
Geoffrey S Johnson
A typical power calculation is performed by replacing unknown population-level quantities in the power function with what is observed in external studies. Many authors and practiti…
Alternative Analysis Methods for Time to Event Endpoints under Non-proportional Hazards: A Comparative Analysis
Ray S. Lin, Ji Lin, Satrajit Roychoudhury +16
The log-rank test is most powerful under proportional hazards (PH). In practice, non-PH patterns are often observed in clinical trials, such as in immuno-oncology; therefore, alter…
Probability-Scale Residuals in HIV/AIDS Research: Diagnostics and Inference
Bryan E. Shepherd, Qi Liu, Valentine Wanga +1
The probability-scale residual (PSR) is well defined across a wide variety of variable types and models, making it useful for studies of HIV/AIDS. In this manuscript, we highlight…